10x Genomics, Inc. (TXG) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$71.48

From 52W high−28.49%

Volume2.52M

Market cap$9.11B

P/E (TTM)—

P/S (TTM)14.8x

Div yield—

Key dataOct 19, 2026

Open

$71.48

From 52W high

−28.49%

Volume

2.52M

Market cap

$9.11B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

229.2x

P/E (TTM)

—

RSI (14)

43.6

MomentumView details →

1D Return

+0.04%

YTD Return

+333.94%

SummaryUpdated Jun 1, 2026

10x Genomics, Inc. (NASDAQ:TXG) is a life sciences technology company founded in 2012 and headquartered in Pleasanton, California. The company went public in September 2019 and has established itself as a leading provider of advanced genomics analysis tools. 10x Genomics develops and commercializes sophisticated instruments, consumables, and software that enable researchers to analyze biological systems at the cellular level with unprecedented detail. The company serves academic institutions, government research facilities, biotechnology companies, and pharmaceutical organizations across North America, Europe, the Middle East, Africa, China, and the Asia Pacific region.

Ask drillr about 10x Genomics, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

229.2x

EV/Sales

14.0x

P/S (TTM)

14.8x

P/B (TTM)

11.0x

ProfitabilityView details →

Gross Margin

70.03%

Net Margin

−12.18%

EBITDA Margin

6.11%

ROE (TTM)

−9.10%

ROA (TTM)

−7.29%

Asset Turnover

0.60x

GrowthView details →

Revenue YoY

−4.28%

EPS YoY

+15.71%

FCF YoY

+113.51%

Revenue CAGR 3Y

+7.57%

EPS CAGR 3Y

+76.97%

EBITDA YoY

+197.73%

MomentumView details →

1D Return

+0.04%

YTD Return

+333.94%

1Y Return

+438.63%

RSI (14)

43.6

vs 50D SMA

−0.69%

vs 200D SMA

+85.85%

Capital & dividendView details →

Debt/Equity

0.10x

Current Ratio

5.69x

Quick Ratio

5.25x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.14

EPS Surprise

42.41%

Beats (12Q)

6/12

Next Q EPS Est

−$0.23

Avg Surprise (4Q)

−18.70%

Rev Surprise

2.97%

Financials snapshotView financials →

Revenue (TTM)

616.91M

Net Income (TTM)

−75.13M

Op. CF (TTM)

127.08M

Next earningsNov 5, 2026 →

Latest newsMore news →

10x Genomics, Inc. announced it will report financial results for the third quarter ended September 30, 2026, after market close on November 5, 2026.6d ago

10x Genomics, Inc. announced a multi-project research collaboration with Fred Hutchinson Cancer Research Center to advance single-cell and spatial technology applications in solid tumors and blood cancers.13d ago

Similar companies

Hinge Health, Inc.HNGE HealthEquity, Inc.HQY Tempus AI, Inc.TEM 麦迪科技603990.SH BrightSpring Health Services, Inc. Common StockBTSG Ping An Healthcare and Technology Company Limited01833.HK Find similar companies →

Latest newsMore news →

10x Genomics, Inc. announced it will report financial results for the third quarter ended September 30, 2026, after market close on November 5, 2026.6d ago 10x Genomics, Inc. announced a multi-project research collaboration with Fred Hutchinson Cancer Research Center to advance single-cell and spatial technology applications in solid tumors and blood cancers.13d ago